Search published articles
Showing 2 results for Nikravesh
Volume 11, Issue 4 (1-2012)
Abstract
This paper proposes a new method of gain scheduling control design for a nonlinear system which is described as linear parameter varying form. A performance measure based on Linear Matrix Inequality is introduced. To consider stability and performance measures in design process, the H∞ loop-shaping method is used to design the local controllers, which can be described as state feedback observer based structure. By introducing the stability and performance covering condition for the linear parameter varying system, a new interpolation law is proposed, and it is proofed that the resultant controller can preserve the performance measure for the observer based structure for all values of the scheduling parameter. Also the closed loop stability is guaranteed. The method is successfully applied on the control of a well-known benchmark system, namely, the autopilot for a pitch-axis model of an air vehicle. The performance and effectiveness is evaluated against disturbances and parameter uncertainties using computer simulation.
Mahbubeh Rojhannezhad, Mehrdad Behmanesh, Abas Nikravesh, Abdolreaza Naser Moghadasi,
Volume 13, Issue 4 (1-2023)
Abstract
Multiple sclerosis (MS) is one of the most common autoimmune diseases in Iran and the world. To date, many drugs have been developed to control the progression of MS as a chronic inflammatory disease of the central nervous system. Rituximab is a chimeric mouse-human monoclonal antibody that binds to the CD20 receptor on the surface of B cells and induces apoptosis. Today, Numerous studies have confirmed the increasing role of non-coding RNAs in regulating the expression of genes and molecular processes, including apoptosis. Furthermore, bioinformatic analysis results indicate that TUG1 LncRNA is differentially expressed in MS patients. Thus, In the present study the possible role of TUG1 in regulating rituximab mechanism of action and apoptosis induction was experimentally investigated. To do this, specific DNAzyme against TUG1 was designed and transfected into Raji cells in the presence or absence of the drug. After transfection, RNA extraction and cDNA synthesis were performed. Then, the expression of target genes was examined by Real-Time PCR technique. The results showed an increase in CD20 expression and a decrease in SMAD2 expression levels. Furthermore, decreased TUG1 gene expression led to an increase in apoptosis and cell accumulation in the G1 phase. It seems that TUG1 expression level can play a significant role in CD20 expression in B cells and therefore on the therapeutic efficacy of rituximab.
